Home » Posts tagged 'technology'
Tag Archives: technology
#TEK Capital investee company #BELL Belluscura PLC – Orders for over 6,500 DISCOV-R™ received
LONDON, U.K. AND PLANO, TX, U.S. (16 August 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received purchase orders for over 6,500 of its next-generation DISCOV-R portable oxygen concentrator. This represents approximately $15 million of potential revenue to the Company, with initial production of the DISCOV-R expected to begin by the end of this quarter.
Following the pre-market launch of DISCOV-R and a patient usability study in June 2023, the Company plans a controlled roll out of the DISCOV-R this autumn and into 2024 to meet growing demand for the device amid substantial interest from medical device distributors, retailers, patients and durable medical equipment (DME) providers, among others.
The DISCOV-R is expected to be the world’s first ambulatory two litre continuous flow, eight level pulse dose portable oxygen concentrator when it is released. With the ability to produce two litres of continuous flow and maximum single pulse dose volumes exceeding 110ml, the Company believes that the DISCOV-R will be covered by both CMS E1390 (stationary) and E1392 (portable) reimbursement codes, making the DISCOV-R a better financial option for the thousands of homecare oxygen providers. It will also produce nearly three times as much oxygen by weight than its dual flow competitors.
The recent purchase orders follow the signing of several distribution agreements with medical device distributors and other home healthcare providers, including a distribution agreement with a division of McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, earlier this month and a marketing agreement with GoodRx®, a leading digital healthcare platform, in February 2023. The Company has received multiple additional requests from leading oxygen homecare providers in the US to distribute the DISCOV-R.
The Company will update the market later this year as it plans its controlled roll out of the DISCOV-R this autumn and into 2024.
Substantial progress on X-PLOR® and proprietary NOMAD biometric app
At the same time, the Company continues to progress its CE and UKCA registration mark application for its X-PLOR® portable oxygen concentrator. Since resources in the US were redirected to completing the development and launch of the DISCOV-R, production of X-PLOR by our Chinese partner, Innomax Medical Technology Ltd (Innomax), has now progressed, with 1,500 units recently being manufactured and shipped to the US for distribution.
The Company recently established a subsidiary and hired its first employees in Shenzhen, China as it prepares for the anticipated registration of the X-PLOR for sale and distribution in China and Hong Kong later this year. The Company and Innomax believe there is a significant market opportunity in China with approximately 100 million people suffering from COPD.
Additionally, the Company continues to drive innovation in telemedicine and artificial intelligence with its proprietary NOMAD biometric app. The NOMAD app will allow users of the DISCOV-R to track performance data on their concentrator and connected devices such as an Apple® or Samsung® Watch, FitBit® device or Nonin® and Masimo® pulse oximeters. The collective information can then be provided to a patient’s healthcare provider in person or remotely.
The Company is already working on the next-generation NOMAD app that will alert patients when their blood oxygen saturation level has varied beyond parameters set by their doctor, which is expected to help patients better monitor their conditions, but also improve the efficiency of the device by delivering supplemental oxygen as needed.
Bob Fary. Sr Vice President of Global Sales, Belluscura plc, commented:
“We are very excited about the overwhelming interest in the DISCOV-R by online retail sellers and other medical equipment providers. Following the pre-market launch of the product and the patient usability study in June, initial feedback suggests we will receive the same or greater level of interest from leading home healthcare providers once it is launched commercially.”
Bob Rauker, Chief Executive Officer, Belluscura plc, commented:
“We believe the DISCOV-R, combined with our proprietary NOMAD app, will be transformational to the portable oxygen industry and patient outcomes. This is reflected by early demand for the product prior to its full commercial launch, which is expected to take place later this year. The significant number of orders received demonstrates the substantial appetite for this product and we anticipate adding several more of these providers to our distribution network as we balance the high demand with production expectations over the next twelve months.
“This marks another exciting development for the Company, delivering on our strategy to design and manufacture highly differentiated, high quality and high margin products. Amid growing sales and continued progress with our X-PLOR device and NOMAD app, we continue to seek further opportunities to improve the quality of life for our end users”.
For further information please contact:
Belluscura plc |
Tel: +44 (0)20 3128 8100 |
Adam Reynolds, Chairman |
|
SPARK Advisory Partners Limited Nominated Adviser |
Tel: +44 (0)20 3368 3550 |
Neil Baldwin / Jade Bayat |
|
Dowgate Capital Limited Broker |
Tel: +44 (0)20 3903 7715 |
James Serjeant / Russell Cook |
|
MHP Financial PR & Investor Relations |
Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com |
Katie Hunt/Matthew Taylor |
#BRES Blencowe Resources PLC – Bulk Sampling Update & China Visit
· Blencowe has successfully completed a critical component of the Definitive Feasibility Study (“DFS”), with the successful scaled commercialisation of the flowsheet within the bulk sample processing at Chinese pilot plant graphite production facility.
· Results continue to highlight a high-grade, low impurity concentrate can be delivered in bulk from Orom-Cross.
· Several meetings held with leading Chinese graphite offtake firms seeking both large flake and fines concentrates.
· Ugandan mining officials visited China with Blencowe and were shown the process facility in support of the project.
· Blencowe now approached for downstream processing opportunities.
Blencowe Resources Plc (“Blencowe” or the “Company”), is pleased to provide an update on the 100 tonne bulk sample processing program currently underway. The work is being completed by a leading graphite technical specialist firm, Jilin New Technology, based in Yanji Province in northern China. This experienced graphite facility has been conducting similar test work on several other leading East African graphite projects over the past few years.
The Company is expecting the bulk sample test program to be completed by the end of August.
Senior Company personnel travelled to China recently to review the progress on the bulk sample processing and broaden relationships in this key market. Accompanying the COO was the Company’s Ugandan Country Manager and a representative of the Ugandan Directorate of Geological Survey and Mines (DGSM), with the express purpose of evaluating the progress of the processing and to demonstrate the full process for the Ugandan Government.
Following a refinement of the Pre-Feasibility Study processing methodology by Wuhan University specialists, Blencowe wished to confirm directly with the pilot plant operators the expected improvements in both overall recovery and concentrate grades and secure early samples for delivery to potential offtake partners, following a marked increase in interest for the projects’ concentrate within China. The 100 tonne pilot plant process is currently nearing completion and to date it is confirming the commercial processing viability of the Orom-Cross ores. The Company also visited operating graphite plants and graphite processing equipment suppliers.
Following the distribution of concentrate samples to potential end users from the IMO test work and Wuhan University 150kg test work, several large downstream offtake processors requested meetings to discuss timing and availability of the high-grade, low impurity concentrates from the Orom-Cross project. The offtake meetings involved firms seeking substantial quantities of both larger flake concentrates and fines feedstock for the SPG processors. Several downstream processing firms have expressed interest in opportunities to explore in-country downstream processing of the Orom-Cross concentrates and Blencowe will consider this within the DFS that is underway.
Blencowe was pleased to be able to escort a representative of the Ugandan Directorate of Geological Survey and Mines to view the final processing of the bulk sample. Blencowe invited the DGSM representative to view the process in order to continue to develop a better understanding of the processing technology involved, to foster a deeper overall understanding of the project within Uganda, and to continue to work in partnership with the Government in order to develop the project.
For further information please contact:
Blencowe Resources Plc Sam Quinn |
www.blencoweresourcesplc.com Tel: +44 (0)1624 681 250
|
Investor Relations Sasha Sethi |
Tel: +44 (0) 7891 677 441
|
Tavira Financial Jonathan Evans |
Tel: +44 (0)20 3192 1733 jonathan.evans@tavira.group
|
First Equity Limited Jason Robertson |
Tel: +44(0)20 7330 1833 jasonrobertson@firstequitylimited.com
|
UKIM Podcast – CEO Alan Green discusses Apple, Amazon, and Harland & Wolff
Alan Green joins the Podcast to discuss Apple and Amazon’s earnings, and the US tech sector. We also provide and overview and analysis of Harland & Wolff.
We discuss:
- Apple (NYSE:AAPL))
- Amazon (NYSE:AMZN)
- Harland & Wolff (LON:HARL)
Listen – https://ukinvestormagazine.co.uk/apple-amazon-and-harland-wolff-with-alan-green/
#TEK TekCapital PLC – Innovation Eyewear Hosts First Smart Eyewear Show
Tekcapital Plc (AIM: TEK, OTCQB: TEKCF), the UK intellectual property investment group announces that Innovative Eyewear, Inc. (“Innovative Eyewear”) (NASDAQ: LUCY; LUCYW), the developer and retailer of smart eyewear under the Lucyd®, Nautica®, and Eddie Bauer® brands, will be holding an Eyewear Fashion Show on April 20th @ 6:00PM EDT at Win 37 Art Gallery, 4320 NW 2nd Ave, Miami, FL 33127 to display its. Lyte 2.0 ChatGPT-enabled smart eyewear line, as part of its Spring 2023 Collection.
Innovative Eyewear believes its new designs and upgrade to the global smart eyewear market can improve the daily lives of people around the world. The Lucyd Lyte® flagship smart eyewear line is reimagining and disrupting the smart eyewear market with a new seamless voice integration with ChatGPT, powered by its patent-pending Lucyd app. Lucyd glasses empower consumers to listen to music, take and make calls, and use voice assistants to perform tasks, and can instantly help individuals tap into ChatGPT’s powerful AI, enabling them to ask ChatGPT just about anything and receive spoken answers.
Harrison Gross, CEO of Innovative Eyewear said:
“From translating languages to looking up recipes and asking questions about pop culture, consumers can verbally ask questions to ChatGPT through microphones seamlessly built into Lucyd glasses and hear the responses through stereo speakers. Additionally, the app may also be used via a streamlined visual interface on iOS/Android, providing the user with both seamless voice and textual interfaces for ChatGPT.
“We believe that our smart eyewear app, integrating ChatGPT, is a paradigm shift in the fashion eyewear market. With our new Lucyd app, which is free during the open beta, we are continuing to make smart eyewear more accessible and functional. It’s our view that a great pair of smart glasses is defined by three key factors: beautiful design, innovative technology, and suitability for all-day wear. The Lyte 2.0 eyewear collection successfully offers these attributes and now provides a fourth factor-access to one of the world’s most popular AI bots. By connecting to ChatGPT via voice commands on Lucyd smart eyewear, users can now access a wealth of detailed information on just about any subject, making smart eyewear a wonderful mobile learning tool.
“Lucyd Lyte® 2.0 eyewear is available in 15 distinct, patent-pending styles, all of which are available with prescription or sunglass lenses, making it one of the most versatile lines of smart eyewear globally. Lucyd smart eyewear makes it easy to use ChatGPT by combining the strength of a natural language AI bot with the natural ergonomic interface of speaking and listening on a hands-free wearable device.
“With this latest debut, Lucyd Smart Eyewear is fusing AI technology and style to disrupt the designer eyewear market by seamlessly integrating ChatGPT via voice commands through Siri or Google Voice. Our Smart glasses go beyond listening to music or taking a phone call-Now consumers can go from stylish and smart to gifted, with audio ChatGPT spoken directly in their ears.
“Lucyd® is an award-winning, patented, smart eyewear brand that is competitively priced with traditional eyewear. With proprietary technology and stylish designs made to elevate customers’ eyewear experience, our eyewear is made to provide the ultimate combination of style and functionality.
“The power of AI chatbots has become undeniable over the last few months. Coupling it with an ergonomic, spoken interface makes it easier to realize its promise. Conversations with AI chatbots are now voice enabled with the Lucyd app and available on-the-go through the entire Lyte 2.0 line.
“We believe Lucyd®’s Spring 2023 collection of men’s and women’s eyewear has the potential to make a serious dent in the fashion smart eyewear market. Our latest generation of smart glasses combines sleek design with open-ear headphones, UV protection, prescription lenses and voice assistance into one innovative, lightweight eyewear product that are equally beautiful and functional.
“With quadrasonic speakers, open-ear audio, noise cancellation microphones, polarized UV 400 lenses and 12-hour battery life seamlessly programmed to work with the world’s smartest Artificial Intelligence platform, Lucyd Lyte is smart eyewear like no other. We believe Lucyd ChatGPT enabled eyewear is the next evolutionary step to Upgrade your Eyewear®.“
Lucyd’s Spring 2023 ChatGPT Enabled Eyewear includes the following models:
Darkside – $199; Darkside Bluetooth smart glasses from Lucyd feature a flat brow design blending mid-century and modern style seamlessly.
Dynamo – $199; Dynamo audio smart glasses offer a refined matte black finish on a bold flat front, an exciting new twist on the classic Roy Orbison silhouette.
Earthbound – $229; The Lucyd Earthbound smart sunglasses offer a fresh tech take on the classic Clubmaster style. An old-school favorite with all-around appeal.
Eclipse – $199; The Lucyd Eclipse audio smart glasses offer an elevated take on the trending crystal-front, black-temple wayfarer.
Electra – $229; The Electra frame from Lucyd is the epitome of bold style offering a matte black brushed titanium front with a glamorous bright gold rim that offers an excellent crossover size that looks great as a sunglass or an eyeglass.
Fusion – $199; The Fusion style offers an excellent crossover size that looks great for both Rx and sunglass wear.
Millennia – $199; The Millennia audio glasses from Lucyd feature a slightly oversized butterfly front in luxurious champagne crystal, with eye-popping glossy white temples.
Moonshot – $199; Trendsetters can experience the apex of sleek design with Moonshot audio glasses from Lucyd, which offers a round-cat shape frame with a lux matte finish.
Nebula – $199; Elevate your style with Nebula audio glasses from Lucyd for a sleek contoured look, offering the perfect frame size for a modern and sophisticated look.
Penubra – $199; Lucyd Penumbra Bluetooth smart glasses offer bold geometric angles that defy the status quo with every contour and offer a futuristic look in glossy black.
Shimmer – $229; Shimmer Lucyd smart glasses bring the ultimate flair of rose gold titanium to smart eyewear for the first time.
Starlyte – $199,; The Lucyd Starlyte smart glasses offer a defined modern cat eye featuring upturned lenses and bowed browline, achieving the perfect symmetrical balance of beauty and elegance.
Starseeker – $229; Lucyd Starseeker titanium audio glasses are made of a brushed gunmetal titanium front and temples, providing an audacious yet sophisticated look.
Stratus – $199; Lucyd Stratus audio glasses are modern and feature subtle features, clean corners and sleek curves, making it the perfect frame for any occasion.
Voyager – $199; Blaze past the limit with the Voyager Bluetooth glass from Lucyd, featuring a trendy acetate aviator shape and a double brow bar.
Download the Lucyd beta app now for a free trial and unlock the possibilities of ChatGPT-enabled smart glasses.
About Innovative Eyewear, Inc.
Innovative Eyewear is a developer and retailer of cutting-edge smart eyewear, under the Lucyd®, Nautica® & Eddie Bauer® brands. True to our mission to Upgrade Your Eyewear®, our Bluetooth audio glasses allow users to stay safely and ergonomically connected to their digital lives, and are offered in hundreds of frame and lens combinations to meet the needs of the optical market. To learn more and explore our continuously evolving collection of smart eyewear, please visit www.lucyd.co.
Tekcapital currently owns 5,189,086 shares (approximately 67%) of Innovative Eyewear, Inc.
For further information, please contact:
Tekcapital Plc |
Via Flagstaff |
|
Clifford M. Gross, Ph.D. |
||
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0) 20 3470 0470 |
|
Richard Morrison/Charlie Bouverat (Corporate Finance)/Abigail Wayne / Rob Rees (Corporate Broking)
|
||
Flagstaff Strategic and Investor Communications |
|
+44 (0) 20 7129 1474 |
Tim Thompson/Andrea Seymour/Fergus Mellon |
|
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
#POLB Poolbeg Pharma – POLB 001 Patent Portfolio Strengthened
· Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia
· Allows for use in combination with an antiviral agent
· Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline
8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia using POLB 001, a small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions.
The USPTO granted a patent for the use of POLB 001 and related p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of hypercytokinaemia (or “cytokine storm”), including hypercytokinaemia that occurs due to viral infection such as an influenza virus, cancer or an autoimmune response, through the modulation of the immune response (reducing the body’s hyperinflammatory response).
Poolbeg has a worldwide license for POLB 001 for all uses in humans and is developing a strong IP portfolio with US patent protection in place covering the use of a wide range of p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of symptoms of severe influenza and hypercytokinaemia and a European patent for the class of p38 MAP kinase inhibitors for use in the treatment of severe influenza.
In January 2022, the Company filed a patent application to seek class protection for the novel use of p38 inhibitors in CAR T cell treatment. This opens up a significant new market opportunity for POLB 001 beyond severe influenza. Poolbeg continues to explore opportunities to expand its IP around this asset to cover new disease areas which could enhance the value of the asset.
The Company continues to work with its patent advisors to broaden and expand its patent families.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“We are expanding our IP portfolio across the globe, allowing us to continue advancing and protecting our programmes for the treatment or prevention of severe influenza and hypercytokinaemia. Enhanced IP protection of our assets across key markets, such as the US, increases the overall value and attractiveness of these products to potential partners. This is particularly important in the light of the recent favourable results from our POLB 001 LPS human challenge trial announced 2 March 2023.”
About POLB 001
POLB 001 is a small molecule immunomodulator for the treatment of symptoms of severe influenza, and hypercytokinaemia which may occur due to exposure to a pathogen or be triggered by cancer or an autoimmune response. Poolbeg continues to discover new indications for POLB 001 in other acute inflammatory conditions. POLB 001 selectively inhibits overwhelming inflammation that may be triggered by viral infections, such as severe influenza, while leaving the necessary immune functions intact to fight the infection. This contrasts with other immunomodulatory approaches, such as steroids, which affect both beneficial and damaging immune responses. Due to its mode of action it is strain agnostic and unaffected by seasonal variants which is a significant advantage over treatments available on the market. In addition, as a shelf stable oral drug it is an ideal stock piling candidate for both seasonal and pandemic outbreaks. Therefore, POLB 001 has the potential to be a transformational treatment for patients and to become a leading severe influenza treatment.
Cytokines, originally intended to optimise immunity, when overexpressed can sweep throughout the body re-programming white blood cells causing tissue damage, shutting down circulation and other essential organs leading to death and in certain circumstances cytokine storm or cytokine release syndrome (CRS). Such excessive cytokine responses can be seen in diseases as diverse as severe influenza and in response to chimeric antigen receptor T cell therapy (CAR T cell) treatment of cancers. Poolbeg continues to evaluate POLB 001’s potential in additional indications to fully unlock the potential value of the molecule.
p38 MAP kinase (p38 MAPK) is a master regulator of immunity, ubiquitously expressed in all white blood cells where it is poised to unleash inflammation. Poolbeg’s clinical approach, inhibiting p38 MAP kinase hypothesised that it’s a prime suspect in driving the cytokine storm and its consequences in patients whose immune responses do not resolve normally, without intervention. This has now been demonstrated as a concept in a human clinical model of infectious disease and endotoxin mediated inflammation administering LPS as the endotoxin to healthy volunteers. LPS is a bacterial product that mimics infection and is used to capture the hallmarks of both local and systemic inflammation typical of a cytokine storm in humans, but in a safe, controlled and quantifiable manner – it’s one step removed from the infected critical care patient. Treatment with POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines and exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo. Read more here.
#TEK Tekcapital Investee – Innovative Eyewear, Inc. Launches New Titanium Styles of Lucyd Lyte® 2.0
Tekcapital Plc (AIM: TEK, OTCQB: TEKCF), the UK intellectual property investment group notes that Innovative Eyewear, Inc. (“Innovative Eyewear”) (NASDAQ: LUCY; LUCYW), the developer and retailer of smart eyewear under the Lucyd®, Nautica® and Eddie Bauer® brands, announces today that five new styles of Lucyd Lyte 2.0 audio eyewear are now available. These new styles are an addition to the 10 styles of Lyte 2.0 introduced in early February. On top of including the major feature upgrades of the Lyte 2.0 such as 12 hours playback per charge, this collection update brings several new design aesthetics to the Lucyd Lyte 2.0 line and the smart eyewear market overall:
1. The Electra frame introduces the first smart eyewear with a two-tone titanium frontplate, bringing the category to a new height of luxurious finishes.
2. The Shimmer frame introduces the first smart eyewear on the US market in a rose gold titanium colour.
3. The Earthbound introduces the best-selling clubmaster style in a Bluetooth format, another first for the US smart eyewear market.
4. The Starlyte style is a key addition developed based on user demand for a cateye style designed for women.
With the introduction of these frames, Lucyd Lyte 2.0 eyewear is now available in 15 distinct styles, the most of any smart eyewear on the US market since the company’s Lyte 1.0 collection. The combination of two different temple lengths, seven styles designed specifically for women, and three styles designed for petite heads, truly open the typically adult male-oriented smart eyewear category to new demographics for the first time.
“With these five new styles of Lyte 2.0 smart eyewear, we are continuing to make the category more accessible than ever before, particularly to women and petite customers by giving them the sizing and styles they need,” says Harrison Gross, CEO of Innovative Eyewear. “A great pair of smartglasses is defined by three key factors: fashion, tech and suitability for all-day vision correction. The Lyte 2.0 collection addresses this successfully by offering smart frames with seamless, user-friendly Bluetooth features, high-end designer styling in a large number of shapes and sizes, and the comfort necessary for all-day wear.”
Watch a video of the new glasses here. Interested retailers are encouraged to visit our booth #P1951 at Vision Expo East 2023 in New York City, or to contact us at info@lucyd.co.
In other news, the popular tech and entertainment site ScreenRant (90m+ monthly visitors) just rated Lucyd Lyte 1.0 eyewear the best on the market.
About Innovative Eyewear, Inc.
Innovative Eyewear is a developer and retailer of cutting-edge smart eyewear, under the Lucyd®, Nautica® & Eddie Bauer® brands. True to our mission to Upgrade Your Eyewear®, our Bluetooth audio glasses allow users to stay safely and ergonomically connected to their digital lives, and are offered in hundreds of frame and lens combinations to meet the needs of the optical market. To learn more and explore our continuously evolving collection of smart eyewear, please visit www.lucyd.co.
Tekcapital currently owns 5,189,086 shares (approximately 68%) of Innovative Eyewear, Inc.
For further information, please contact:
Tekcapital Plc |
Via Flagstaff |
|
Clifford M. Gross, Ph.D. |
||
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0) 20 3470 0470 |
|
Richard Morrison/Charlie Bouverat (Corporate Finance)/Abigail Wayne / Rob Rees (Corporate Broking)
|
||
Flagstaff Strategic and Investor Communications |
|
+44 (0) 20 7129 1474 |
Tim Thompson/Andrea Seymour/Fergus Mellon |
|
About Tekcapital plc
Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.
LEI: 213800GOJTOV19FIFZ85
Forward-Looking Statements
This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Innovative Eyewear, Inc., Lucyd or Tekcapital that may constitute forward-looking statements. These statements may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Tekcapital, Innovative Eyewear Inc. or Lucyd’s management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Innovative Eyewear Inc., Lucyd and/or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Other than as required by relevant regulation or law, neither Innovative Eyewear Inc, Lucyd nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.